Ms. Lydia CAI
Managing Director TPG CapitalMs. Lydia Li Cai joined TPG in August 2011 and is latest serving as a managing director of TPG, a leading global alternative asset firm.
Ms. Cai was responsible for the control buyout of United Family Healthcare (“UFH”) in 2014 and the trade sale of UFH to New Frontier Healthcare in 2019. Ms. Cai was responsible for the control buyout of two clinical CROs, PPC and Novotech in 2017. These two companies have merged to form Novotech Health Holdings. Ms. Cai was also responsible for the growth minority investments in Kangji Medical, Shanghai Bio-heart, Zhaoke Ophthalmology, Shanghai Ark Biosciences and Dingdang Health. She was also responsible for the successful trade sale of UniTrust Leasing and China Grand Auto.
Ms. Cai is currently a board member of Novotech Health Holdings, Kangji Medical, Dingdang Health and Chongho Bridge.
From March 2009 to July 2011, Ms. Cai worked as an investment associate at HAO Capital, responsible for growth stage healthcare investments. From 2007 through 2008, Ms. Cai worked as a research analyst at Credit Suisse AG (New York), where she was responsible for equity research for large cap medical supplies and devices companies.
Ms. Cai obtained a bachelor’s degree in biomedical engineering and economics from Yale University in May 2007.